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Oxygen measurement in the BM indicated that normal and 
malignant hematopoiesis occur under hypoxic conditions 
(Spencer et al., 2014). Hif-1 and Hif-2 are key mediators of 
cellular responses to hypoxia and regulate gene expression to 
facilitate adaptation to low oxygen tension (Semenza, 2014). 
Oxygen-regulated α-subunits of Hif-1 and Hif-2, namely 
Hif-1α and Hif-2α, are paralogs that have common and also 
distinct functions during responses to hypoxia. Several stud-
ies investigated the role of Hif-1α (Wang et al., 2011; Velas-
co-Hernandez et al., 2014) and Hif-2α (Rouault-Pierre et al., 
2013) in acute myeloid leukemia (AML; Gezer et al., 2014; 
Vyas, 2014). HIF-1α or HIF-2α knockdown in AML patient 
samples compromised their ability to reconstitute AML upon 
transplantation into recipient mice (Wang et al., 2011; Rou-
ault-Pierre et al., 2013). Although the subtype and molecular 
classification of AML samples used in these studies were not 
specified, the authors implied that HIF-1 and HIF-2 are in-
dependently required for the maintenance of AML leukemic 
stem cells (LSCs), suggesting that HIF-1 and HIF-2 are po-
tential therapeutic targets for AML (Wang et al., 2011; Rou-
ault-Pierre et al., 2013).
Considering the caveats of shRNA-mediated gene 
knockdown approaches, a recent study used a conditional 
Hif-1α knockout and reported that, surprisingly, conditional 
Hif-1α deletion does not compromise the development 
and maintenance of mouse LSCs generated by the MLL-
ENL fusion, its downstream effectors Meis1 and Hoxa9, and 
Aml1-Eto9a (Velasco-Hernandez et al., 2014). In fact, loss of 
Leukemogenesis occurs under hypoxic conditions within the bone marrow (BM). Knockdown of key mediators of cellular re-
sponses to hypoxia with shRNA, namely hypoxia-inducible factor-1α (HIF-1α) or HIF-2α, in human acute myeloid leukemia 
(AML) samples results in their apoptosis and inability to engraft, implicating HIF-1α or HIF-2α as therapeutic targets. How-
ever, genetic deletion of Hif-1α has no effect on mouse AML maintenance and may accelerate disease development. Here, we 
report the impact of conditional genetic deletion of Hif-2α or both Hif-1α and Hif-2α at different stages of leukemogenesis 
in mice. Deletion of Hif-2α accelerates development of leukemic stem cells (LSCs) and shortens AML latency initiated by 
Mll-AF9 and its downstream effectors Meis1 and Hoxa9. Notably, the accelerated initiation of AML caused by Hif-2α deletion 
is further potentiated by Hif-1α codeletion. However, established LSCs lacking Hif-2α or both Hif-1α and Hif-2α propagate 
AML with the same latency as wild-type LSCs. Furthermore, pharmacological inhibition of the HIF pathway or HIF-2α knockout 
using the lentiviral CRI SPR-Cas9 system in human established leukemic cells with MLL-AF9 translocation have no impact on 
their functions. We therefore conclude that although Hif-1α and Hif-2α synergize to suppress the development of AML, they 
are not required for LSC maintenance.
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Hif-1α accelerated the development of Meis1/Hoxa9-in-
duced AML or enhanced propagation of disease induced by 
Aml1-Eto9a (Velasco-Hernandez et al., 2014). This study 
concluded that Hif-1α can suppress LSC development or 
propagation and is dispensable for AML LSC maintenance, 
sparking a debate over the therapeutic benefit of targeting 
HIF-1 function (Vyas, 2014).
To date, the impact of conditional deletion of Hif-2α or 
loss of both Hif-1α and Hif-2α on leukemic transformation 
has not been examined. Therefore, in this study, we set out to 
investigate the requirement for Hif-2α or both Hif-1α and 
Hif-2α in the development and maintenance of AML LSCs.
RES ULTS AND DIS CUSSI ON
Hif-2α suppresses the development of LSCs  
but has no impact on AML propagation  
in a Meis1/Hoxa9-induced murine AML
To investigate the requirement for Hif-2α in leukemogenesis, 
we used a well-characterized mouse model of AML in which 
the development and maintenance of LSCs is driven by co-
expression of Meis1 and Hoxa9 oncogenes (Lessard and Sau-
vageau, 2003; Wang et al., 2010; Lehnertz et al., 2014). These 
two oncogenes are frequently overexpressed in several human 
AML subtypes (Lawrence et al., 1999; Drabkin et al., 2002) 
and their overexpression in mouse hematopoietic stem and 
progenitor cells (HSPCs) promotes self-renewal and perturbs 
their differentiation, resulting in the generation of self-renew-
ing LSCs (Kroon et al., 1998). In the Meis1/Hoxa9 model 
used in this study, the BM c-Kit+ HSPC population, which 
contains all of the cellular targets for leukemic transformation, 
is transduced with retroviruses expressing Meis1 and Hoxa9. 
After three rounds of replating, it gives rise to the population of 
preleukemic cells that, upon transplantation to primary recipi-
ents, generates LSCs, thereby causing AML with a long latency 
(Fig. 1 A). LSCs are defined by their capacity to propagate AML 
with short latency in secondary recipients (Fig. 1 A). To estab-
lish the functional significance of Hif-2α in leukemogenesis, 
we used mice with Vav-iCre–mediated hematopoiesis-specific 
deletion of Hif-2α (Hif-2αfl/fl;Vav-iCre mice), which we previ-
ously demonstrated to have normal numbers of hematopoietic 
stem cells (HSCs) and progenitor cells and display no hemato-
poietic defects (Guitart et al., 2013). We transduced c-Kit+ cells 
from Hif-2αfl/fl;Vav-iCre and control (Hif-2αfl/fl without Vav-
iCre) mice with Meis1/Hoxa9 retroviruses and serially replated 
them under normoxic and hypoxic conditions. Hif-2α–defi-
cient and control cells displayed similar replating capacity and 
generated comparable numbers of compact colonies at each 
passage (Fig. 1, B and C). Operetta high-content automated 
microscope analyses revealed that the colonies of both geno-
types had comparable sizes (unpublished data). Flow cytometry 
analyses of the CFC3 colonies using c-Kit, Mac-1, and Gr-1 
markers revealed no differences in immunophenotypic com-
position of colonies of the two genotypes (unpublished data).
Proliferation assays and cell cycle analyses on Hif-2α–
deficient preleukemic cells (i.e., cells obtained after the third 
round of replating) cultured under hypoxia and normoxia 
revealed that Hif-2α–deficient cells had increased prolif-
erative capacity (Fig.  1  D) and that a larger proportion of 
Hif-2α–deficient cells were in S and G2/M phases of cell 
cycle compared with control cells (Fig.  1 E). Thus, Hif-2α 
is not required for the generation of preleukemic cells but 
restricts their proliferative capacity.
To investigate the impact of Hif-2α deletion on LSC 
generation, we transplanted Hif-2α–deficient and control 
preleukemic cells generated under normoxic conditions 
into primary recipient mice (Fig. 1 A). Blood sampling re-
vealed that a significantly smaller proportion of recipients 
of Hif-2α–deficient cells remained leukemia-free compared 
with recipients of control preleukemic cells (Fig. 1 F). Con-
sequently, recipients of Hif-2α–deficient cells had decreased 
survival compared with recipients of control preleukemic 
cells (Fig. 1 G). Analyses of BM from leukemic primary recip-
ient mice revealed that Meis1/Hoxa9-transduced control and 
Hif-2αfl/fl;Vav-iCre preleukemic cells generate leukemia with 
the same immunophenotypic characteristics (unpublished 
data). In conclusion, Hif-2α suppresses the establishment of 
LSCs and delays the onset of Meis1/Hoxa9-induced AML.
To investigate the ability of Hif-2α–deficient LSCs to 
propagate leukemia, we sorted the CD45.2+ donor-derived 
c-Kit+ cell population (that contains LSCs; Somervaille et al., 
2009) from the two cohorts of leukemic primary recipients 
and transplanted equal numbers of c-Kit+ cells into second-
ary recipients. LSCs of both genotypes generated aggressive 
AML with similar latency (Fig.  1  H). Therefore, Hif-2α is 
not required for the maintenance of LSCs and their ability to 
propagate Meis1/Hoxa9–induced AML.
Hif-2α deletion accelerates LSC development 
but does not affect LSC maintenance in a mouse 
model of Mll-AF9–driven AML
We next set out to confirm the ability of Hif-2α to sup-
press the development of AML in the Mll-AF9 knock-in 
(Mll-AF9KI/+) mouse model of human AML (Dobson 
et al., 1999; Chen et al., 2008; Kumar et al., 2009). This 
model is thought to closely mimic the human disease, as 
each cell contains a single copy of the Mll-AF9 fusion on-
cogene, physiologically expressed from the endogenous Mll 
promoter. In this model, Mll-AF9KI/+ Lin−Sca-1+c-Kit+ 
(LSK) stem and primitive progenitor cells are sufficient 
to initiate leukemia with long latency upon transplanta-
tion. We generated Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre mice 
and controls, i.e., Mll-AF9KI/+;Hif-2αfl/fl (without Vav-
iCre), Hif-2αfl/fl;Vav-iCre, and Hif-2αfl/fl mice and trans-
planted LSK cells from these mice into primary recipients 
(together with 200,000 WT CD45.1+ unfractionated BM 
cells). We found that recipients of Mll-AF9KI/+;Hif-2αfl/fl; 
Vav-iCre and Mll-AF9KI/+;Hif-2αfl/fl LSK cells had similar 
percentages of CD45.2+ donor-derived cells indicating that 
the overall reconstitution capacity of LSK cells of both gen-
otypes was not different. Furthermore, LSK cells of both 
 o
n
 D
ecem
ber 7, 2015
jem.rupress.org
D
ow
nloaded from
 
Published December 7, 2015
3JEM 
Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre and Mll-AF9KI/+;Hif-2αfl/fl gen-
otypes had multilineage differentiation potential that was 
sustained for at least 19 wk after transplantation (not de-
picted). However, recipients of Mll-AF9KI/+;Hif-2αfl/fl;Vav-
iCre LSK cells had increased percentages of donor-derived 
myeloid cells in the peripheral blood compared with recip-
ients of Mll-AF9KI/+;Hif-2αfl/fl LSK cells (Fig. 2 A). Conse-
quently, recipients of Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre LSK 
cells became cachectic and succumbed to AML (confirmed 
by flow cytometric analyses of the BM; not depicted) faster 
compared with recipients of Mll-AF9KI/+;Hif-2αfl/fl LSK 
cells (Fig.  2, B and C). This was in contrast to recipients 
of Hif-2αfl/fl;Vav-iCre and Hif-2αfl/fl LSK cells which, as 
expected (Guitart et al., 2013), did not develop leukemia 
(Fig. 2, B and C). To investigate whether Hif-2α deletion 
compromises LSC maintenance in the Mll-AF9KI/+ model, 
we sorted the CD45.2+ donor-derived Lin−c-Kit+Sca-1− 
(LK) cells from primary recipients and transplanted them 
into secondary recipients (together with 200,000 WT 
CD45.1+ unfractionated BM cells). LK cells of both Mll-
AF9KI/+;Hif-2αfl/fl and Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre 
genotypes equally efficiently engrafted (Fig. 2 D), and prop-
agated full-blown disease (Fig. 2 E) in secondary recipients. 
We also tested the LSC frequency in primary recipients of 
Mll-AF9KI/+;Hif-2αfl/fl or Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre 
LSK cells that developed leukemia by performing a second-
ary transplantation of donor-derived LK cells sorted from 
primary leukemic recipients using an extreme limiting di-
lution assay (Hu and Smyth, 2009) and found no differ-
ence in LSC frequency between the genotypes (Table 1 and 
Table 2). We conclude that Hif-2α delays the development 
of LSCs in the Mll-AF9 model of AML, but once LSCs are 
established Hif-2α is dispensable for their maintenance.
CRI SPR-Cas9–mediated HIF-2α ablation  
has no impact on human AML cells
Given our surprising findings, which indicated that Hif-2α 
is not required for mouse AML propagation, we next deter-
Figure 1. Hif-2α deletion accelerates LSC development but has no impact on LSC maintenance. (A) CD45.2+c-Kit+ cells from Hif-2αfl/fl;Vav-iCre 
and control (Vav-iCre-negative) mice were cotransduced with Meis1 and Hoxa9 retroviruses and serially replated under normoxic (N) and hypoxic (H; 1% 
O2) conditions and were subjected to in vitro assays. 100,000 c-Kit+ preleukemic cells generated under normoxia were transplanted into lethally irradiated 
CD45.1+/CD45.2+ recipients. CD45.2+c-Kit+ LSCs from primary recipients were transplanted to secondary recipients. (B) Colony-forming cell (CFC) assay 
counts at each replating. Data are mean ± SEM (n = 3–5). (C) Representative colonies generated at CFC3. Bars, 70 µm. (D) Proliferation curves of preleuke-
mic cells in liquid cultures under normoxia and hypoxia. Data are mean ± SEM (n = 3). (E) The cell cycle analysis of preleukemic cells under normoxia and 
hypoxia. Data are mean ± SEM (n = 3–4). (F) The percentage of leukemia-free mice defined as mice that have <1% of leukemic cells in the peripheral blood 
(n = 8–10 recipients per biological replicate [n = 3]). (G) Kaplan-Meier survival curve of recipients transplanted with 100,000 c-Kit+ preleukemic cells (n = 
8–10 recipients per biological replicate [n = 3]). (H) Secondary transplantation. 10,000 CD45.2+c-Kit+ LSCs sorted from primary recipients were transplanted 
into secondary recipients. Data are mean ± SEM (n = 8–10 recipients per biological replicate [n = 2]). At least two independent experiments were performed 
for all analyses. Statistical analysis: Mann-Whitney test. *, P < 0.05; **, P < 0.005; ***, P < 0.001.
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Figure 2. Hif-2α deletion in Mll-AF9KI/+ mice accelerates AML development but has no impact on its propagation. 2,000 CD45.2+Lin−Sca-1+c-
Kit+ (LSK) cells were sorted from 18-wk-old Hif-2αfl/fl (Vav-iCre-negative), Hif-2αfl/fl;Vav-iCre, Mll-AF9KI/+;Hif-2αfl/fl, and Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre mice 
and transplanted into lethally irradiated CD45.1+/CD45.2+ recipients (together with 200,000 CD45.1+ BM cells per recipient). (A) Percentage of CD45.2+-
Mac-1+Gr-1+ cells in peripheral blood at week 4 and 10. Data are mean ± SEM (n = 3–8 recipients per biological replicate [n = 2]). (B) Ratio of weight of 
primary recipients at week 17 compared with week 4. (C) Kaplan-Meier survival curve of primary recipients transplanted with 2,000 LSK cells of the indicated 
genotypes. Data are mean ± SEM (n = 3–8 recipients per biological replicate [n = 2]). (D) 5,000 CD45.2+Lin−c-Kit+Sca-1− (LK) cells were sorted from primary 
recipients and transplanted into secondary recipients (together with 200,000 CD45.1+ BM cells per recipient). Percentage of CD45.2+Mac-1+Gr-1+ cells in 
peripheral blood at week 9. Data are mean ± SEM (n = 5–6 recipients per biological replicate [n = 2]). (E) Kaplan-Meier survival curve of secondary recipient 
mice transplanted with 5,000 LK cells of the genotypes indicated in Fig. 2 C (n = 5–6 recipients per biological replicate [n = 2]). At least two independent 
experiments were performed for all analyses. Statistical analysis: Mann-Whitney test. *, P < 0.05; ***, P < 0.001.
Table 1. Extreme limiting dilution assay (ELDA)
Cell dose Mll-AF9KI/+;Hif-2αfl/fl Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre
50 4/8 6/12
500 8/8 10/10
5,000 10/10 15/15
Secondary recipients were transplanted with 50, 500, or 5,000 LK cells of the indicated genotypes sorted from primary recipients. Number of mice (out of total injected) that showed en-
graftment of CD45.2+ cells in the peripheral blood at week 9 (n = 6–15 per group) are listed. All calculations and statistical analyses were done using the ELDA algorithm (Hu and Smyth, 
2009). Three independent experiments were performed.
Table 2. ELDA confidence intervals
LSC frequency Confidence intervals (95%)
Mll-AF9KI/+;Hif-2αfl/fl Mll-AF9KI/+;Hif-2αfl/fl;Vav-iCre
Lower 1/185 1/157
Estimate 1/71.7 1/71.9
Upper 1/27.9 1/33.1
Secondary recipients were transplanted with 50, 500, or 5,000 LK cells of the indicated genotypes sorted from primary recipients. Lower, estimate, and upper LSC frequency represented as 
1/(indicated number of cells) at a 95% confidence interval are shown. All calculations and statistical analyses were done using the ELDA algorithm (Hu and Smyth, 2009). Three independent 
experiments were performed.
 o
n
 D
ecem
ber 7, 2015
jem.rupress.org
D
ow
nloaded from
 
Published December 7, 2015
5JEM 
mined the impact of HIF-2α ablation in human leukemic 
cells using the CRI SPR-Cas9 genome editing approach. 
We transduced human AML (M5) THP-1 cells harboring 
MLL-AF9 translocation with lentiviruses expressing two in-
dependent single guide RNAs (sgRNAs) targeting exon 12 
of the HIF-2α (EPAS1) gene (Fig. 3, A and B) and coexpress-
ing a mammalian codon-optimized Cas9 nuclease (Sanjana 
et al., 2014). These lentiviruses will be referred to as HIF-2α 
sgRNA1-Cas9 and HIF-2α sgRNA2-Cas9. We isolated two 
independent clones, one harboring HIF-2α sgRNA1-Cas9 
lentivirus and the second harboring sgRNA2-Cas9 len-
tivirus (Fig.  3 A). Both clones had frameshifting mutations 
(Fig. 3 B), resulting in the loss of HIF-2α protein (Fig. 3 D). 
Two clones of THP-1 cells transduced with Cas9 lentivirus 
lacking sgRNA were used as control. Our analyses performed 
under normoxic and hypoxic conditions revealed that the 
loss of HIF-2α expression had no impact on the cell cycle 
(Fig.  3 E), proliferation rate (Fig.  3  F), and colony forma-
tion capacity (Fig. 3, G–I) of THP-1 cells under normoxic 
and hypoxic conditions. Thus, consistent with our find-
ings in the mouse models of AML, HIF-2α is not required 
for propagation of human leukemic cells under normoxic 
and hypoxic conditions.
Hif-1α and Hif-2α synergize to suppress the development 
of AML but are dispensable for disease propagation
The tumor suppressor function of Hif-2α in AML devel-
opment, taken together with the recent study indicating 
that Hif-1α can also suppress leukemic transformation (Ve-
lasco-Hernandez et al., 2014), suggested that Hif-1α and 
Hif-2α may collaborate to suppress leukemogenesis. To test 
this, we transduced BM-derived c-Kit+ cells from Hif-1αfl/
fl;Vav-iCre, Hif-2αfl/fl;Vav-iCre, Hif-1αfl/fl;Hif-2αfl/fl;Vav-
iCre, and control mice with Meis1/Hoxa9 retroviruses. 
Although cells of each genotype cultured under normoxia 
and hypoxia self-renewed equally in serial replating assays 
(Fig. 4 A), preleukemic cells lacking Hif-1α, Hif-2α, or both 
had increased proliferative capacity compared with control 
cells (Fig. 4 B). After transplantation, the cell cycle profile of 
Hif-1α–deficient cells was not different from that of control 
cells but a slightly larger proportion of Hif-2α–deficient and 
Hif-1α/Hif-2α–deficient cells were in S/G2/M phases of 
the cell cycle compared with Hif-1α–deficient cells (no-
tably there was no difference in the cell cycle profile be-
tween Hif-2α–deficient and Hif-1α/Hif-2α–deficient cells; 
unpublished data). Remarkably, upon transplantation, pre-
leukemic cells lacking both Hif-1α and Hif-2α generated 
dramatically accelerated AML compared with those lack-
ing either Hif-1α or Hif-2α (Fig. 4, C and D). Therefore, 
Hif-1α and Hif-2α synergize to suppress the development 
of LSCs. Finally, control, Hif-2α- and Hif-1α/Hif-2α–de-
ficient BM c-Kit+ cells sorted from primary leukemic re-
cipients equally efficiently generated aggressive leukemia 
in secondary recipients (Fig.  4  E). Thus, despite the hy-
poxic nature of the BM, at least in AML involving Meis1/
Hoxa9-mediated transformation the disease is propagated 
through Hif-independent mechanisms.
Pharmacological inhibition of the HIF pathway does not 
affect human AML cell survival and proliferation
To test the impact of inhibiting the HIF pathway in human 
AML cells, we incubated (M5) THP-1 cells and NOMO-1 
cells, both harboring the MLL-AF9 fusion, with BAY 87–
2243, which inhibits HIF-1α and HIF-2α protein accumula-
tion under hypoxia and decreases HIF target gene expression 
in tumor cells (Ellinghaus et al., 2013; Helbig et al., 2014; 
Chang et al., 2015). As expected, BAY 87–2243 treatment in-
hibited the expression of HIF target genes (ALD OA, PDK1, 
BNIP3, and EGLN3) in both THP-1 (Fig. 5 A) and NOMO-1 
(Fig. 5 B) cells under hypoxia. Under these conditions, BAY 
87–2243 had no effect on the proliferative capacity and sur-
vival of THP-1 (Fig. 5, C and D) and NOMO-1 (Fig. 5, E 
and F) cells. Thus, inhibition of the HIF pathway in two inde-
pendent, established human AML cells with MLL-AF9 trans-
location has no impact on their survival and growth.
Hif-1α and Hif-2α deletion promotes a gene  
expression signature that facilitates survival  
and proliferation of preleukemic cells
To understand the molecular signatures associated with ac-
celerated leukemia development upon Hif-1α and Hif-2α 
deletion, we performed global gene expression profiling of 
Meis1/Hoxa9-transduced Hif-1αfl/fl;Vav-iCre, Hif-2αfl/fl; 
Vav-iCre, Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre, and control preleu-
kemic cells incubated under hypoxic conditions (1% O2) 
for 8 d. Although deletion of Hif-1α or Hif-2α had a minor 
effect on gene expression (i.e., 87 and 6 genes were differ-
entially expressed in Hif-1αfl/fl;Vav-iCre and Hif-2αfl/fl;Vav-
iCre cells, respectively, compared with control cells), deletion 
of both Hif-1α and Hif-2α deregulated the expression of 
1,013 genes (Fig.  6, A and B; FDR< 0.05), indicating the 
synergism between Hif-1α and Hif-2α in the control of gene 
expression. Indeed, multiple known Hif target genes identi-
fied previously in nonhematopoietic cells (Mole et al., 2009; 
Schödel et al., 2011) were deregulated in Hif-1αfl/fl;Hif-2αfl/fl; 
Vav-iCre preleukemic cells (Fig.  6  C). Strikingly, pathways 
analyses revealed that the most significantly affected group 
of genes deregulated upon Hif-1α and Hif-2α deletion were 
genes involved in energy metabolism. Whereas genes involved 
in glycolysis were significantly down-regulated in Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre cells, those controlling fatty acid degra-
dation, the TCA cycle, and mitochondrial oxidative phos-
phorylation pathways were up-regulated in preleukemic cells 
lacking Hif-1α and Hif-2α (Fig. 6, D and E). Thus, the ability 
of Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre cells to generate accelerated 
leukemia is associated with the gene signature indicative of 
the metabolic switch from glycolysis to fatty acid oxidation 
and mitochondrial oxidative phosphorylation.
In addition to the pathways analyses, our data revealed 
that a subset of modulators of AML leukemogenesis was de-
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Figure 3. CRI SPR-Cas9–mediated HIF-2α 
gene targeting in human THP-1 leukemic 
cells has no impact on their survival, pro-
liferation, or colony formation. (A) Exper-
imental design. Human THP-1 leukemic cells 
were transduced with bi-cistronic lentiviruses 
expressing one of two independent sgRNAs 
targeting exon 12 of human HIF-2α (these 
sgRNAs are referred to as HIF-2α sgRNA1 and 
HIF-2α sgRNA2) and a mammalian codon-op-
timized Cas9. Control-Cas9 constructs lack the 
20-nt sequence within the sgRNA necessary 
for HIF-2α targeting. After single-cell cloning, 
the clones with the correctly targeted HIF-2α 
gene (and two control clones) were subjected 
to functional assays. (B) Design of sgRNAs 
to knock out human HIF-2α. Two indepen-
dent sgRNAs (i.e., HIF-2α gRNA1 and HIF-2α 
gRNA2) were designed to target exon 12 of 
human HIF-2α gene. Target sequences are in-
dicated in red. Top sequences indicate the WT 
allele of HIF-2α. Bottom sequences indicate 
the deletions in the HIF-2α gene, all of which 
resulted in frameshift mutations. (C) Sche-
matic representation of a bi-cistronic lentiviral 
vector allowing for the expression of HIF-2α 
sgRNA1 or HIF-2α sgRNA2 from a U6 pro-
moter (U6) and Cas9 from an EF1α short pro-
moter (EFS). Psi+, Psi packaging signal; RRE, 
Rev response element; P2A, Picorna virus–
derived 2A self-cleaving peptide; Puro, puro-
mycin selection cassette; WPRE, Woodchuck 
hepatitis virus posttranscriptional regulatory 
element. (D) THP-1 cells transduced with Con-
trol-Cas9, HIF-2α sgRNA1-Cas9, and HIF-2α 
sgRNA2-Cas9 lentiviruses were incubated 
with CoCl2 to enhance HIF-2α stability. West-
ern blot analysis was performed to determine 
the levels of HIF-2α. Hypoxic MCF-7 breast 
cancer cell line was used as a positive control 
for HIF-2α. (E) The cell cycle analysis of THP-1 
cells transduced with Control-Cas9, HIF-2α 
sgRNA1-Cas9, and HIF-2α sgRNA2-Cas9 len-
tiviruses incubated under normoxic and hy-
poxic (1% O2) conditions. Data are mean ± 
SEM. (F) Proliferation assays under normoxia 
and hypoxia. Data are mean ± SEM, (G) Colony 
numbers automatically counted at day 11 after 
plating. Cells were plated in methylcellulose 
at a density of 400 cells per well in a 96-well 
plate and grown under either normoxic or hy-
poxic conditions. Plates were imaged at 37°C 
and 5% CO2 on an Operetta automated microscope on day 11. For each well, six fields of view were acquired at each of the five focal planes separated by 150 
µm, ensuring no double counting of colonies. Data are mean ± SEM. (H) Colony size was calculated in an unbiased way by the Operetta microscope software 
at day 11 after plating using the Harmony texture-based image analysis software. Data are mean ± SEM. (I) Morphology of representative colonies cultured 
under normoxia and hypoxia and photographed at day 11 after plating. Bars, 120 µm. For A–I, the data with two independent control THP-1 cell clones and 
two independent HIF-2α–deficient clones (expressing HIF-2α sgRNA1-Cas9 and HIF-2α sgRNA2-Cas9, respectively) are shown. Technical triplicates for each 
clone were used. At least two independent experiments were performed for all analyses. Statistical analysis: Mann-Whitney test.
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regulated upon Hif-1α and Hif-2α deletion. The expression of 
several negative regulators of leukemogenesis was decreased, 
and the expression of distinct genes that promote AML was 
increased (Fig. 6 F). For example, the expression of a direct 
Hif target Kdm5b (Jarid1b) which functions as a H3K4-spe-
cific demethylase that negatively regulates leukemogenesis in 
murine and human MLL-rearranged AML cells (Wong et al., 
2015), was decreased in Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre cells 
(notably, Kdm5b knockdown in MLL-rearranged cells de-
creases the latency of AML development; Wong et al., 2015). 
Levels of Tspan3 (encoding tetraspanin 3), which is required 
for the development and propagation of AML (Kwon et al., 
2015), were increased (Fig.  6 F). A hypoxia-inducible gene 
Bnip3 (Sowter et al., 2001), encoding a proapoptotic protein 
that is silenced in hematopoietic malignancies, including 17% 
of AML cases (Murai et al., 2005), was down-regulated in Hif-
1αfl/fl;Hif-2αfl/fl;Vav-iCre cells (Fig.  6  F). Furthermore, one 
of the most significantly up-regulated pathways in Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre cells was the proteasome pathway (Fig. 6, 
D and E), whose expression and activity is increased in ma-
lignancies, including leukemia (Kumatori et al., 1990; Ma et 
al., 2009), and inhibition of which reduces survival of human 
and mouse AML cells (Servida et al., 2005; Bernot et al., 
2013; van der Helm et al., 2015). Finally, consistent with their 
increased proliferation, numerous genes involved in cell cycle 
progression or tumorigenesis were differentially expressed in 
Hif-1α/Hif-2α–deficient preleukemic cells compared with 
control (unpublished data). Therefore, Hif-1α and Hif-2α de-
letion promotes a molecular signature that facilitates survival 
and proliferation of preleukemic cells.
The role of Hif-1α and Hif-2α in leukemic transforma-
tion remains a subject of intense debate (Losman and Kaelin, 
2013; Gezer et al., 2014; Vyas, 2014). Here, we used a condi-
tional gene deletion approach to investigate the requirement 
for Hif-1α and Hif-2α in leukemogenesis. Neither Hif-1α 
nor Hif-2α was essential for the generation of preleukemic 
cells in vitro under normoxic and hypoxic conditions. No-
tably, however, loss of Hif-2α accelerated the conversion 
of preleukemic cells to LSCs and shortened AML latency, 
and this effect was potentiated by Hif-1α codeletion. Our 
data, taken together with the tumor suppressor functions of 
Hif-1α (Velasco-Hernandez et al., 2014), imply that Hif-1α 
and Hif-2α synergize within the hypoxic bone marrow to 
suppress LSC generation and AML development. Although 
deletions in HIF-1α or HIF-2α have not been thus far iden-
tified in any subtype of human AML (Ley et al., 2008; Can-
cer Genome Atlas Research Network, 2013; Andersson et al., 
2015; Lavallée et al., 2015), it will be of interest to explore the 
Figure 4. Hif-1α and Hif-2α synergize to suppress LSC development in a murine Meis1/Hoxa9-mediated AML. (A) CFC assay counts at each 
replating. Data are mean ± SEM (n = 5). (B) Proliferation curves of preleukemic cells in liquid cultures under normoxia and hypoxia. Data are mean ± 
SEM (n = 3). (C) The percentage of leukemia-free recipient mice transplanted with control (Vav-iCre-negative), Hif-1α–deficient, Hif-2α–deficient, and 
Hif-1α/Hif-2α–deficient preleukemic cells (n = 4–5 recipients per biological replicate [n = 2]). (D) Kaplan-Meier survival curve of recipients transplanted 
with 100,000 c-Kit+ preleukemic cells of the indicated genotypes. n = 4–5 recipients per biological replicate (n = 2). (E) Secondary transplantation. 10,000 
CD45.2+c-Kit+ LSCs sorted from primary recipients of control, Hif-2α–deficient and Hif-1α/Hif-2α–deficient preleukemic cells were retransplanted into 
secondary recipients. Data are mean ± SEM (n = 8–10 recipients). At least two independent experiments were performed for all analyses. Statistical analysis: 
Mann-Whitney test. *, P < 0.05; **, P < 0.005; ***, P < 0.001; ****, P < 0.0001.
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possibility that HIF-1α or HIF-2α are mutated or silenced 
in leukemias with MLL translocations or in those expressing 
high levels of MEIS1 or HOXA9.
Gene knockdown studies suggested the requirement 
for HIF-1α or HIF-2α in human LSC functions, indicat-
ing that HIFs are potential therapeutic targets for AML LSC 
elimination (Wang et al., 2011; Rouault-Pierre et al., 2013). 
However, the interpretation of these knockdown studies is 
confounded by the lack of information regarding the subtype 
and cytogenetics of AML samples. Here, we report that, sur-
prisingly, Hif-2α is dispensable for the ability of established 
LSCs to sustain murine AML induced by Mll-AF9 or Meis1/
Hoxa9. Remarkably, established LSCs lacking both Hif-1α 
and Hif-2α efficiently propagate AML. Furthermore, CRI 
SPR-Cas9–mediated knockout of HIF-2α or pharmaco-
logical inhibition of the HIF pathway in human AML cells 
with MLL-AF9 translocation had no impact on their survival 
and proliferation under hypoxic conditions. Thus, our study 
in mouse and human cells, taken together with the recent 
demonstration that Hif-1α is dispensable for disease propaga-
tion in MLL-ENL– and Meis1/Hoxa9-driven mouse AML 
(Velasco-Hernandez et al., 2014), indicates that HIF antago-
nists are unlikely to have a major beneficial therapeutic po-
tential in AML subsets resulting from the activation of the 
Mll–AF9–Meis1/Hoxa9 pathway. Finally, given the hetero-
geneity of AML, we propose that the systematic dissection 
of the roles of HIF-1α and HIF-2α in different AML subsets 
is required to identify those that are sensitive to the inhibi-
tion of HIF-1 and/or HIF-2.
Collectively, we provide genetic evidence that Hif-2α 
acts as a tumor suppressor in the development of AML, but is 
dispensable for LSC maintenance, at least within Mll–AF9–
Meis1/HoxA9-driven leukemia. In concordance, the HIF 
pathway is not essential in human AML cells harboring the 
MLL–AF9 translocation. Finally, at least in the Meis1/Hoxa9 
AML model, Hif-1α and Hif-2α are not required for LSC 
Figure 5. Pharmacological targeting of 
the HIF pathways in human leukemic cells 
has no impact on their survival under hy-
poxic conditions. THP-1 and NOMO-1 cells 
were incubated for 6 d under hypoxic con-
ditions (1% O2) with BAY 87–2243 (10nM) 
or vehicle control (0.001% EtOH [vol/vol]). 
Expression levels of HIF target genes ALD OA, 
PDK1, BNIP3, and EGLN3 in (A) THP-1 cells 
and in (B) NOMO-1 cells. Results are expressed 
as fold change (2−(ΔΔCT)) over vehicle control 
cultured in normoxia. HPRT was used as the 
reference gene and data are represented as 
mean ± SEM (n = 3 technical replicates per 
cell line). *, P < 0.05; **, P < 0.005; ***, P < 
0.001; ****, P < 0.0001. THP-1 (C and D) and 
NOMO-1 (E and F) cells were plated at a den-
sity of 400,000 cells/ml and incubated with 10 
nM BAY 87–2243 or vehicle control (0.001% 
EtOH [vol/vol]) under hypoxic conditions (1% 
O2). At day 3 and 6, the cells were incubated 
with 7-AAD and their proliferative capacity 
(number of 7-AAD− cells) and percentage of 
dead (7-AAD+) cells was measured by flow 
cytometry using the BD Accuri C6 Flow Cy-
tometer. (C) Proliferation and (D) percentage 
of dead THP-1 cells treated with BAY 87–2243 
or vehicle control under hypoxic conditions is 
shown. (E) Proliferation and (F) percentage of 
dead NOMO-1 cells treated with BAY 87–2243 
or vehicle control under hypoxic conditions is 
shown. For A–F, data are mean ± SEM (n = 3 
technical replicates). At least two independent 
experiments were performed for all analyses. 
Statistical analysis: Mann-Whitney test.
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maintenance and AML propagation, but they act synergisti-
cally to suppress LSC development. Considering that LSCs 
serve as a paradigm for other cancer stem cells, it will be in-
teresting to investigate the synergistic tumor suppressor func-
tions of Hif-1 and Hif-2 in other cancers.
MAT ERIALS AND MET HODS
Mice. Hif-1αfl/fl;Vav-iCre, Hif-2αfl/fl;Vav-iCre, and Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre mice were described previously (Guitart 
et al., 2013). Mll-AF9KI/+ mice (Chen et al., 2008) were ob-
tained from The Jackson Laboratory. 8–10-wk-old sex-
matched mice were used as donors of c-Kit+ cells. Animal 
experiments were approved by the Animal Welfare and Ethi-
cal Review Body of the University of Edinburgh and autho-
rized by the UK Home Office.
FACS. BM and blood samples were stained and analyzed as 
described previously (Kranc et al., 2009; Guitart et al., 2013).
Figure 6. Molecular signature of preleukemic cells lack-
ing Hif-1α, Hif-2α or both. Gene expression profiling was 
performed in Hif-1αfl/fl;Vav-iCre, Hif-2αfl/fl;Vav-iCre, Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre, and control preleukemic cells (n = 4–5 bi-
ological replicates per genotype) cultured under hypoxic con-
ditions (1% O2) for 8 d. (A) Expression scatterplots showing 
relative mean expression of Affymetrix probes between control 
(x-axis) and Hif-1αfl/fl;Vav-iCre, Hif-2αfl/fl;Vav-iCre or Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre (DKO) cells (y-axis). Significantly deregulated 
genes are shown in red (P < 0.05). (B) Venn diagram shows sig-
nificantly deregulated (P < 0.05) genes in Hif-1αfl/fl;Vav-iCre, 
Hif-2αfl/fl;Vav-iCre, and Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre preleu-
kemic cells. (C) Heat map showing a log2 fold change in the 
expression of HIF-1 and/or HIF-2 target genes (Schödel et al., 
2011) in Hif-1α–, Hif-2α–, and Hif-1α/Hif-2α–deficient preleu-
kemic cells relative to control preleukemic cells. The heat map 
shows all HIF-1 and/or HIF-2 target genes that are significantly 
deregulated in Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre cells (P < 0.05) 
compared with control cells. (D) KEGG pathway annotations 
in Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre (DKO) versus control cells. Path-
way enrichment is presented as –log10 (p-value). The dotted 
orange line indicates P = 0.05. (E) Heat map showing a log2 fold 
change (vs. control preleukemic cells) in expression of genes 
belonging to the glycolysis, fatty acid metabolism, TCA cycle, 
oxidative phosphorylation, and proteasome pathways that are 
significantly (P < 0.05) deregulated in Hif-1αfl/fl;Hif-2αfl/fl;Vav-
iCre cells. (F) Heat map showing a log2 fold change (vs. control 
preleukemic cells) in expression of genes involved in AML leuke-
mogenesis. All genes are significantly deregulated in Hif-1αfl/fl; 
Hif-2αfl/fl;Vav-iCre cells (P < 0.05) compared with control cells. 
(E and F) *, HIF-1 target gene; **, HIF-1 and HIF-2 target gene 
(Schödel et al., 2011).
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RNA isolation and quantitative real-time polymerase chain 
reaction (qRT-PCR). Total RNA was isolated using the 
RNeasy Mini kit (QIA GEN) and cDNA synthesis was per-
formed with the High-Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems). qRT-PCR was performed in 
triplicate with the Light Cycler 480-II (Roche) using the 
human TaqMan Gene Expression Assay probe and primer sets 
for HPRT (Hs02800695_m1), BNIP3 (Hs00969291_m1), 
PDK1 (Hs01561850_m1), EGLN3 (Hs00222966_m1), and 
ALD OA (Hs00605108_g1; Life Technologies). Relative gene 
expression was analyzed by the ΔΔCt method using HPRT as 
reference control and an assigned calibrator.
Gene expression profiling and bioinformatics analyses. Pre-
leukemic cells cultured in hypoxia (1% O2) were collected 
and resuspended in TRIzol (Life Technologies). RNA was 
isolated by standard phenol/chloroform extraction. RNA 
samples (500 ng) were processed and labeled for array hy-
bridization using the Ambion WT Expression kit (Life 
Technologies). Labeled, fragmented cDNA (GeneChip WT 
Terminal Labeling and Controls kit; Affymetrix) was hybrid-
ized to Mouse Gene 2.0 arrays for 16 h at 45°C (at 60 rpm; 
GeneChip Hybridization, Wash, and Stain kit; Affymetrix). 
Arrays were washed and stained using the Affymetrix Fluid-
ics Station 450, and scanned using the Hewlett-Packard Ge-
neArray Scanner 3000 7G.
For bioinformatic analyses, a total of 18 arrays (n = 5 
for control, n = 4 for Hif-1αfl/fl;Vav-iCre, n = 5 for Hif-2αfl/fl; 
Vav-iCre, n = 4 for Hif-1αfl/fl;Hif-2αfl/fl;Vav-iCre) were QC 
(quality control) analyzed using arrayQualityMetrics in Bio-
conductor. Raw data were quantile normalized across all 
arrays. Pairwise group comparisons were undertaken using 
linear modeling, using the limma package in Bioconductor. 
Subsequently, empirical Bayesian analysis was applied, includ-
ing vertical (within a given comparison) p-value adjustment 
for multiple testing, which controls for false-discovery rate. 
Functional-enrichment hypergeometric test analyses were 
performed for KEGG pathways using the appropriate pack-
ages. Focused genes of interest lists were assembled from the 
literature and other publically available resources.
Immunoblotting. THP-1 cells were incubated with 150 µM 
CoCl2 (Sigma-Aldrich) for 16 h, washed in ice-cold phos-
phate-buffered saline (PBS), and prepared in lysis buffer con-
taining 6.7 M urea, 10 mM Tris-Cl, pH 6.8, 10% glycerol, 1% 
SDS, 1 mM dithiothreitol, supplemented with Complete Pro-
tease Inhibitor and PhosStop (Roche). 20 µg of proteins were 
separated by electrophoresis on a 10% Tris-Glycine gel and 
transferred to Immun-Blot polyvinylidene difluoride mem-
branes (Bio-Rad Laboratories). Membranes were blocked in 
3% milk 3% BSA in Tris-buffered saline – 0.1% Tween-20 
(TBST), and then incubated with HIF-2α primary antibody 
(NB100-122; Novus) in 3% milk 3% BSA TBST overnight, 
washed in TBST, and incubated with horseradish peroxidase 
(HRP) –labeled secondary antibodies (R&D Systems) in 3% 
milk TBST. Immunodetection was performed using the Su-
persignal West Dura Extended Duration Substrate (Thermo 
Fisher Scientific) and Odyssey Fc (Licor Biosciences).
Leukemic transformation assays. BM cells were extracted 
from 8–10-wk-old mice. After c-Kit enrichment using 
MACS LS columns (Miltenyi Biotec), cells were transduced 
with MSCV-Meis1a-puro and MSCV-Hoxa9-neo retrovi-
ruses and serially replated every 6 d in MethoCult M3231 
(STE MCELL Technologies) supplemented with SCF, IL-3, 
IL-6, and GM-CSF in normoxia (20% O2) and hypoxia (1% O2).
Cell cycle and proliferation assays. Live cells were counted 
with Accuri C6 Flow Cytometer (BD) at the time points 
indicated in the figures. For cell cycle analyses, cells were re-
suspended in the DAPI/NP-40 solution and acquired 
on FAC SFortessa V (BD).
CRI SPR/Cas9 gene targeting. Guide RNAs to target the 
human HIF-2α gene were designed using the Zhang 
laboratory web resource (www .genome -engineering .org). 
Two individual sgRNAs were designed to target exon 12 of 
HIF-2α (sgRNA1, 5′-AGA AGACA GAGCC CGAGC AC-3′; 
sgRNA2, 5′-GCT TCCGG CATCA AAGAA GA-3′), which 
is the most 5′ exon common to all UCSC-annotated 
transcript variants. sgRNA-encoding oligonucleotides were 
cloned into pLentiCRI SPRv2 vector (Sanjana et al., 2014) 
using standard procedures (www .genome -engineering .org). 
Lentiviral production was performed as described previously 
(Kranc et al., 2009). After lentiviral transduction and selection, 
THP-1 cells were subjected to single-cell sorting (FAC SAria 
Fusion; BD), and individual clones were expanded and 
screened for frameshift mutations. In brief, a region spanning 
the target site was amplified from genomic DNA isolated 
from individual clones. PCR products were subsequently 
cloned into TOPO TA Cloning Sequencing vector 
(Invitrogen). 15 sequences were analyzed per clone by 
aligning them to the WT HIF-2α sequences using BLA ST. 
Only the clones with frameshifting indel mutations and no 
detectable WT allele were used for subsequent 
validation and in vitro assays.
Cell culture for drug studies. THP-1 and NOMO-1 cells 
were cultured at 400,000 cells/ml in RPMI-1640 GlutaMAX 
containing 10% FBS, 25 mM HEP ES, 100 U/ml penicillin, 
and 100 µg/ml streptomycin and incubated with 10 nM BAY 
87–2243 (Selleckchem) or vehicle control (0.001% EtOH 
[vol/vol]) for 6 d under hypoxic conditions (1% O2). At days 
3 and 6, the cells were incubated with 7-AAD, and their pro-
liferative capacity (number of 7-AAD− cells) and percentage 
of dead (7-AAD+) cells was measured by flow cytometry 
using the Accuri C6 Flow Cytometer (BD).
Transplantation assays. Mll-AF9KI/+, Hif-1αfl/fl, Hif-2αfl/fl, and 
Vav-iCre mice were CD45.2+. For transplantations with 
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Meis1/Hoxa9-expressing preleukemic cells, 100,000 c-Kit+ 
preleukemic cells were transplanted together with 200,000 WT 
CD45.1+ unfractionated BM cells into lethally irradiated (10 
Gy) CD45.1+/CD45.2+ recipients. The mice were monitored 
for AML development. For secondary transplants with Meis1/
Hoxa9-expressing LSCs, 10,000 CD45.2+c-Kit+ cells were 
sorted from primary recipients and transplanted into secondary 
recipients together with 200,000 WT CD45.1+ unfractionated 
BM cells. For Mll-AF9KI/+ cell transplantations, lethally irradi-
ated CD45.1+/CD45.2+ syngeneic recipients were trans-
planted with 2,000 LSK or 5,000 LK cells (together with 
200,000 CD45.1+ BM cells per recipient) as indicated in Fig. 2.
Statistical analysis. Kaplan-Meier survival curve statistics 
were determined using the Mantel-Cox test. LSC frequencies 
were determined using ELDA statistics software (Hu and 
Smyth, 2009). All other statistical significance was determined 
using the Mann-Whitney test.
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